Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study

Table 1 Demographic and Baseline Characteristics^a

Characteristic	Total Population (n = 56)
Age (y), mean ± SEM	40.2 ± 1.0
Age of onset (y), mean ± SEM	17.9 ± 1.3
Currently employed, No. (%)	49 (88)
Migraine type, No. (%)
MRM	51 (91)
MM	5 (9)
Pain location, No. (%)
Bilateral	17 (30)
Unilateral	39 (70)
Average duration of untreated/unsuccessfully treated attacks, No. (%)
< 12 h	2 (4)
12 to < 24 h	15 (27)
24 to < 48 h	7 (13)
48 to < 72 h	14 (25)
≥ 72 h	18 (32)
Analgesic medications used, No. (%)
NSAID	17 (30)
NSAID plus triptan	20 (36)
NSAID plus a butalbital/caffeine/propyphenazone combination medication	1 (2)
Triptan	18 (32)
Other prophylactic medication use, No. (%)^b	33 (59)

Abbreviations: MM, menstrual migraine, MRM menstrually related migraine, NSAID nonsteroidal anti-inflammatory drug, nVNS non-invasive vagus nerve stimulation, SEM standard error of the mean
^aData represent values from the baseline period
^bAmitriptyline (5/56), coenzyme Q10/ginkgolide B/riboflavin (tablets) plus magnesium (4/56), coenzyme Q10/ginkgolide B/riboflavin/magnesium (granulated) (1/56), coenzyme Q10/ginkgolide B/riboflavin/magnesium (granulated) plus amitriptyline (1/56), magnesium (3/56), β-blocker (2/56), calcium channel blocker (2/56), paroxetine (2/56), riboflavin (2/56), amitriptyline plus benzodiazepine (1/56), amitriptyline plus magnesium (1/56), β-blocker plus amitriptyline (1/56), botulinum toxin A (1/56), sodium valproate plus venlafaxine (1/56), sodium valproate plus paroxetine (1/56), tanacetum parthenium (1/56), sertraline (1/56), topiramate plus sertraline (1/56), topiramate plus gabapentin (1/56)

ISSN: 1129-2377